Research Roundup

Debbie Rigby takes a look at the latest research news Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease In this large double-blind event-driven trial, ticagrelor (90 mg twice daily) was not shown to be superior to clopidogrel (75 mg once daily) for the reduction of cardiovascular events in patients with symptomatic peripheral artery disease. Major